Measured by its ability to neutralize CD30 Ligand/TNFSF8-induced IL‑6 secretion in the HDLM human Hodgkin’s lymphoma cell line. The Neutralization Dose (ND50) is typically 3-10 µg/mL in the presence of 500 ng/mL Recombinant Mouse CD30 Ligand/TNFSF8 and 10 µg/mL of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody.
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
IL‑6 Secretion Induced by CD30 Ligand/TNFSF8 and Neutralization by Mouse CD30 Ligand/TNFSF8 Antibody. In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (10 µg/mL, Catalog # MAB050), Recombinant Mouse CD30 Ligand/TNFSF8 (Catalog # 732-CL) stimulates IL‑6 secretion in the HDLM human Hodgkin’s lymphoma cell line in a dose-dependent manner (orange line), as measured by the Human IL‑6 Quantikine ELISA Kit (Catalog # D6050). Under these conditions, IL‑6 secretion elicited by Recombinant Mouse CD30 Ligand/TNFSF8 (500 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Mouse CD30 Ligand/TNFSF8 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF732). The ND50 is typically 3‑10 µg/mL.
Preparation and Storage
Reconstitute at 0.2 mg/mL in sterile PBS.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CD30 Ligand/TNFSF8
CD30 Ligand (CD30L)/TNFSF8 is a type II membrane protein belonging to the TNF superfamily. CD30L is expressed on the cell surface of activated T cells, B cells, and monocytes. The protein is also constitutively expressed on granulocytes and medullary thymic epithelial cells. The specific receptor for CD30L is CD30/TNFRSF8, a type I transmembrane glycoprotein belonging to the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkin's and Reed-Sternberg cells using the monoclonal antibody Ki-1. CD30 is also expressed on different non-Hodgkin's lymphomas, virus-infected T and B cells, and on normal T and B cells after activation. Among T cells, CD30 is preferentially expressed on a subset of T cells producing Th2-type cytokines and on CD4+/CD8+ thymocytes that coexpress CD45RO and IL-4 receptor. CD30 ligation by CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation and cell death by apoptosis. CD30 can act as a co‑stimulatory molecule in thymic negative selection and may also play a critical role in the pathophysiology of Hodgkin's disease and other CD30+ lymphomas.
Brunangelo, F. et al. (1995) Blood 85:1.
Gruss, H-J. and F. Herrmann (1996) Leukemia and Lymphoma 20:397.
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.